Skip to main content
Skip to main content
INFU logo

InfuSystem Holdings, Inc. (INFU) Stock Analysis

$8.93 +$0.01 (+0.11%) |Exceptional · 84
Signals are mixed — the Council read leans Bullish Lean (68/100) while the AI fundamental score is 84/100 (grade A+); the two lenses disagree, so weigh the breakdown below. Strongest single signal: Seth Klarman bullish.
MCap: $180M| P/E Ratio: 32.1| Vol: 178.1K| Target: $15.00 (+68.0%)|
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

InfuSystem Holdings, Inc. (INFU) trades at $8.93 with AI Score 84/100 (Grade A+). InfuSystem Holdings, Inc. provides infusion pumps and related services across the United States and Canada. Market cap: $180M, Sector: Healthcare.

Price as of Jul 20, 2026 · Last analyzed: May 10, 2026
InfuSystem Holdings, Inc. provides infusion pumps and related services across the United States and Canada. The company operates through two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services), serving oncology and home care markets.

INFU stock analysis for 2026: Analysts have set a consensus price target of $15.00 for InfuSystem Holdings, Inc., suggesting 68.0% upside from the current price of $8.93. The AI MoonshotScore is 84/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Watch the INFU film Every key number, told as a short cinematic story — just press play. ~2 min
Council Score · Weighted Average of 3 Disciplines
Bullish Lean 68/100 · B+

INFU: 1/3 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.

How is this calculated? →
MoonshotScore · Growth Potential · 84/100
Business Quality
Strong Is this a genuinely good business?
Financial Safety
Moderate Could this blow up on me?
Valuation
Strong Am I paying a fair price?
Growth Durability
Strong Is the growth real and likely to last?
Momentum
Moderate Is the market already moving on this?
Legends Council · 5 Legends + Moon AI
Ray Dalio
Bullish
Ken Griffin
Bullish
Izzy Englander
Neutral
Seth Klarman
Bullish
Moon AI
Bullish
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Neutral
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →

Why this analysis is different

  • A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
  • An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
  • Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

InfuSystem Holdings, Inc. (INFU) Healthcare & Pipeline Overview

CEOCarrie A. Lachance
Employees502
HeadquartersRochester Hills, MI, US
IPO Year2007

InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services in the US and Canada, focusing on oncology and home care markets. The company differentiates itself through its integrated therapy services and durable medical equipment offerings, catering to a diverse range of healthcare settings.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 10, 2026

What Is the Investment Thesis for INFU?

As of May 10, 2026 — figures reflect the data available on that date.

InfuSystem Holdings, Inc. presents a compelling investment case based on its established market position and growth potential within the infusion therapy sector. The company's dual-segment strategy, encompassing both integrated therapy services and durable medical equipment, provides diversification and resilience. A key value driver is the increasing demand for ambulatory infusion pumps in oncology and home care settings, fueled by an aging population and the shift towards outpatient care. The company's gross margin of 56.7% indicates strong profitability and efficient operations. However, investors should be aware of the potential risks associated with regulatory changes and competitive pressures within the medical device industry. The company's P/E ratio of 32.1 suggests a reasonable valuation relative to its earnings.

Based on FMP financials and quantitative analysis

INFU Key Highlights

  • Market Cap of $180M reflects the company's current valuation in the market.
  • P/E Ratio of 32.1 indicates the price investors are willing to pay for each dollar of earnings.
  • Profit Margin of 5.6% demonstrates the company's ability to generate profit from its revenue.
  • Gross Margin of 56.7% showcases the efficiency of the company's production and service delivery.
  • Beta of 1.55 suggests that the stock is more volatile than the market average.

Who Are INFU's Competitors?

INFU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
PDEX Pro-Dex, Inc. $54.66 -4.74% $175M 81
UTMD Utah Medical Products, Inc. $69.30 -0.72% $221M 89
OPSSF Opsens Inc. $2.14 +0.65% $247M 58
TSNLF Tristel PLC $5.28 +0.00% $253M 53
ARTC ArthroCare Corp. $9.97 +0.00% $260M 64
NNNN Anbio Biotechnology $9.52 +0.32% $418M 55
SPMXF Supermax Corporation Berhad $0.15 +0.00% $459M 54
NYXH Nyxoah S.A. $1.56 -0.64% $61.8M 69

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are INFU's Key Strengths?

  • Strong market position in infusion therapy services.
  • Comprehensive product and service offerings.
  • Established relationships with healthcare providers.
  • Dual-segment strategy providing diversification.

What Are INFU's Weaknesses?

  • Reliance on a limited number of key customers.
  • Exposure to regulatory changes and compliance requirements.
  • Competition from larger medical device companies.
  • Potential for product liability claims.

What Could Drive INFU Stock Higher?

  • Expansion of the DME Services segment into new geographic markets.
  • Strategic partnerships with major hospital networks to increase market penetration.
  • Launch of new infusion pump technologies with enhanced features in Q4 2026.
  • Increasing demand for home-based infusion therapy due to cost savings and patient convenience.

What Are the Key Risks for INFU?

  • Rich valuation — a P/E of 32.1 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
  • Regulatory changes affecting the approval and reimbursement of infusion pumps.
  • Increased competition from larger medical device companies with greater resources.
  • Economic downturn leading to reduced healthcare spending.
  • Product liability claims related to the use of infusion pumps.
  • Dependence on key suppliers for critical components and materials.

What Are the Growth Opportunities for INFU?

  • Expansion in Home Healthcare Market: The increasing preference for home-based healthcare presents a significant growth opportunity for InfuSystem. As healthcare costs rise and technology advances, more patients are opting for treatment in the comfort of their homes. InfuSystem can capitalize on this trend by expanding its DME Services segment, offering a wider range of durable medical equipment and support services tailored to the home healthcare market. This includes providing training and education to patients and caregivers on the proper use and maintenance of infusion pumps. The home healthcare market is projected to reach $367 billion by 2029, offering substantial growth potential.
  • Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, oncology clinics, and home infusion providers can drive growth for InfuSystem. By forming strategic partnerships, the company can secure long-term contracts and increase its market share. These partnerships can involve joint marketing efforts, integrated service offerings, and shared technology platforms. For example, InfuSystem could partner with a major hospital network to become the preferred provider of infusion pumps and related services across the network's facilities. Such partnerships can also facilitate the adoption of InfuSystem's products and services by a wider range of healthcare professionals.
  • Product Innovation and Technological Advancement: Investing in research and development to create innovative infusion pump technologies can provide a competitive edge for InfuSystem. This includes developing pumps with enhanced features, such as wireless connectivity, remote monitoring, and improved safety mechanisms. The company can also explore the integration of its pumps with telehealth platforms, enabling remote patient monitoring and virtual consultations. By staying at the forefront of technological advancements, InfuSystem can attract new customers and retain existing ones. The global medical device market is expected to reach $600 billion by 2028, highlighting the importance of innovation.
  • Geographic Expansion within North America: While InfuSystem already operates in the United States and Canada, there is potential for further geographic expansion within these markets. This includes targeting underserved regions and establishing a stronger presence in key metropolitan areas. The company can achieve this through a combination of organic growth and strategic acquisitions. For example, InfuSystem could acquire a smaller DME provider in a high-growth region to expand its market reach. Geographic expansion can also involve establishing new service centers and distribution networks to better serve customers in different areas.
  • Diversification into Related Healthcare Services: InfuSystem can explore opportunities to diversify its service offerings beyond infusion pumps and related products. This could include providing specialized training programs for healthcare professionals, offering consulting services to hospitals and clinics, or developing software solutions for managing infusion therapy. By diversifying its revenue streams, InfuSystem can reduce its reliance on a single product category and enhance its overall financial stability. The healthcare services market is projected to reach $10 trillion by 2027, indicating the potential for growth through diversification.

What Opportunities Does INFU Have?

  • Expansion into new geographic markets.
  • Development of innovative infusion pump technologies.
  • Strategic partnerships with healthcare providers.
  • Growth in the home healthcare market.

What Threats Does INFU Face?

  • Increased competition from existing and new players.
  • Pricing pressures from healthcare providers and payers.
  • Technological obsolescence of existing products.
  • Economic downturn affecting healthcare spending.

What Are INFU's Competitive Advantages?

  • Established relationships with healthcare providers.
  • Specialized expertise in infusion pump technology and services.
  • Comprehensive customer support network.
  • Dual-segment strategy providing diversification.

What Does INFU Do?

InfuSystem Holdings, Inc., established in 2005 and headquartered in Rochester Hills, Michigan, operates as a key provider of infusion pumps and related products and services within the United States and Canada. The company functions through two primary segments: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment focuses on supplying electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics. These products are crucial for the treatment of various cancers, including colorectal cancer, as well as for pain management and other disease states. The DME Services segment is involved in the sale, rental, and leasing of both new and pre-owned pole-mounted and ambulatory infusion pumps, along with other durable medical equipment. This segment also sells treatment-related consumables and provides biomedical recertification, maintenance, and repair services. InfuSystem serves a wide array of healthcare settings, including oncology practices, home care and home infusion providers, skilled nursing facilities, pain centers, and hospitals. The company distinguishes itself through its comprehensive customer support, including local and field-based assistance, as well as dedicated pump service and repair centers, ensuring reliable and efficient service delivery.

What Products and Services Does INFU Offer?

  • Supplies electronic ambulatory infusion pumps.
  • Provides disposable supply kits for infusion pumps.
  • Offers pumps for oncology, infusion, and hospital outpatient chemotherapy clinics.
  • Provides pumps for treatment of cancers, pain management, and other disease states.
  • Sells, rents, and leases new and pre-owned infusion pumps.
  • Sells treatment-related consumables.
  • Provides biomedical recertification, maintenance, and repair services.
  • Offers local and field-based customer support.

How Does INFU Make Money?

  • Sells infusion pumps and related supplies to healthcare providers.
  • Rents and leases infusion pumps to hospitals and clinics.
  • Provides maintenance and repair services for infusion pumps.
  • Generates revenue from both Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services).

What Industry Does INFU Operate In?

InfuSystem Holdings, Inc. operates within the medical instruments and supplies industry, a sector characterized by continuous innovation and increasing demand for advanced medical technologies. The market for infusion pumps is driven by the rising prevalence of chronic diseases, the growing geriatric population, and the shift towards home healthcare. The industry is competitive, with players ranging from large multinational corporations to smaller specialized companies. InfuSystem distinguishes itself through its focus on integrated therapy services and durable medical equipment, catering to specific needs within the oncology and home care markets. The company's ability to provide comprehensive support and maintenance services further strengthens its competitive position.

Who Are INFU's Key Customers?

  • Oncology clinics and hospitals.
  • Home care and home infusion providers.
  • Skilled nursing facilities.
  • Pain centers.
AI Confidence: 72% Updated: May 10, 2026

How InfuSystem Holdings, Inc. Is Valued

Relative to its peer group, INFU's quantitative score of 84/100 is above the peer average of 69/100.

F-Score 8/9Financial Health

InfuSystem Holdings, Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.95 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project InfuSystem Holdings, Inc. revenue of about $144.8M for fiscal 2026, with EPS near $0.42. The estimate reflects 3 contributing analysts.

INFU Financials

Fundamental Snapshot

Revenue Growth (FY)
+6.4%
Net Income Growth (FY)
+182.6%
EPS Growth (FY)
+190.9%
P/E (TTM)
22.5
Return on Equity (TTM)
+14.0%
Current Ratio
2.1
EV/EBITDA (TTM)
7.7

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • InfuSystem's recent insider buying suggests that those with the closest view of the company's prospects are optimistic about its future.
  • The community sentiment is leaning towards a positive outlook, with many believing in the company's long-term growth potential.
  • The market perceives InfuSystem as a key player in its niche, with potential for expansion into new markets.
  • Recent developments in the healthcare sector are seen as favorable to InfuSystem's business model.

Bear Case

  • Some insiders may be selling off shares, which could signal concerns about the company's short-term performance.
  • Bearish community members are expressing worries about increased competition pressuring margins.
  • The market is showing some skepticism about InfuSystem's ability to maintain its growth trajectory.
  • Recent regulatory changes in the healthcare industry may pose challenges to InfuSystem's operations.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

INFU Latest News

INFU Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INFU.

Price Targets

Consensus target: $15.00

INFU MoonshotScore

84/100

What does this score mean?

The MoonshotScore rates INFU 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.

Leadership: Carrie A. Lachance

CEO

Carrie A. Lachance serves as the Chief Executive Officer of InfuSystem Holdings, Inc. Her background includes extensive experience in the healthcare industry, with a focus on medical devices and services. Prior to joining InfuSystem, she held leadership positions at various healthcare companies, where she was responsible for driving growth, improving operational efficiency, and enhancing customer satisfaction. Her expertise spans across sales, marketing, and product development.

Track Record: Under Carrie A. Lachance's leadership, InfuSystem Holdings, Inc. has focused on expanding its market share and enhancing its service offerings. Key achievements include strengthening relationships with healthcare providers and driving innovation in infusion pump technology. Her strategic decisions have contributed to the company's growth and profitability. She manages 502 employees.

INFU Healthcare Stock FAQ

What does the AI Score mean for INFU?

INFU holds an AI Score of 84/100 (Grade: A+). This is an educational research signal, not a buy or sell recommendation. InfuSystem Holdings, Inc. provides infusion pumps and related services across the United States and Canada. The company operates through two segments, Integrated Therapy Services (ITS) and Durable …

What does InfuSystem Holdings, Inc. do?

InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services in the United States and Canada. The company operates through two segments: Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The ITS segment supplies electronic ambulatory infusion pumps and disposable supply kits to oncology clinics and hospitals for cancer treatment and pain management.

What do analysts say about INFU stock?

Analyst coverage of InfuSystem Holdings, Inc. (INFU) focuses on the company's growth prospects within the infusion therapy market and its ability to maintain profitability. Key valuation metrics include the P/E ratio of 32.1, which reflects investor expectations for future earnings growth. Analysts also consider the company's gross margin of 56.7% as an indicator of operational efficiency.

What are the main risks for INFU?

The main risks for InfuSystem Holdings, Inc. include regulatory changes affecting the approval and reimbursement of infusion pumps, increased competition from larger medical device companies, and potential product liability claims. The company is also exposed to economic downturns that could reduce healthcare spending. Dependence on key suppliers for critical components and materials is another risk factor. Effective risk management and compliance strategies are crucial for mitigating these potential challenges.

What are the key factors to evaluate for INFU?

InfuSystem Holdings, Inc. (INFU) holds an AI score of 84/100 (high). P/E: 32.1x vs the S&P 500's ~20-25x. Analysts target $15.00 (+68%). Not financial advice.

How frequently does INFU data refresh on this page?

INFU's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.

What has driven INFU's recent stock price performance?

InfuSystem Holdings, Inc. (INFU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in infusion therapy services. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider INFU overvalued or undervalued right now?

InfuSystem Holdings, Inc. (INFU) trades at 32.1x earnings. Analysts target $15.00 (+68%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research INFU before investing?

Before investing in InfuSystem Holdings, Inc. (INFU), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Financial data is based on the most recent available information.
  • Analyst opinions may vary and should be considered as part of a comprehensive investment analysis.
Data Sources

Popular Stocks